KPTI News and Press, Karyopharm Therapeutics Inc. From 07/19/23

Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th PR Newswire - Data Provide Further Support for Company's Ongoing Phase 3 St...

2023-07-18 09:49:15 ET A Massachusetts-based healthcare company is turning heads on Tuesday after the company announced after hours yesterday that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to the development program of %Selinexor for the tre...

Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis PR Newswire – Regulatory Designation Includes Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis – ...

Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis PR Newswire Phase 3 Study is Supported by Previously Presented Phase 1 Study Results, Including a 78.6% SVR35 and 58.3% TSS50 in Intent t...

Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings PR Newswire NEWTON, Mass. , May 23, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage...

2023-05-06 19:46:03 ET Karyopharm Therapeutics, Inc. (KPTI) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Re...

2023-05-05 14:28:53 ET Summary Karyopharm Therapeutics cut its 2023 guidance, resulting in a 25% drop in stock price. Increased use of Patient Assistance Programs (PAPs) was cited as the primary reason for reduced revenue projections. Other potential factors, in my view, inclu...

2023-05-04 16:09:48 ET Shares of Karyopharm Therapeutics (NASDAQ: KPTI) were down more than 26% Thursday afternoon after the biotech company released first-quarter earnings and updated its guidance. The stock fell to its lowest point since it was $2.51 a share on Dec. 28, 2022. ...

2023-05-04 13:00:26 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q1 2023 Earnings Call May 04, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q1 2023 Earni...

2023-05-04 12:56:38 ET Shares of Karyopharm Therapeutics ( NASDAQ: KPTI ) fell ~24% on Thursday to hit the lowest level since December after the oncology-focused biotech trimmed its full-year outlook despite beating Wall Street forecasts with its Q1 2023 financials. Due to a...